Adherence to rivaroxaban for the treatment of venous thromboembolism – results from the FIRST registry
No Thumbnail Available
Authors
Speed, Victoria
Auyeung, Vivian
Patel, Jignesh P.
Cooper, Derek
Miller, Stephen
Roberts, Lara N.
Patel, Raj K.
Arya, Roopen
Check for full-text access
Issue Date
2021
Type
Article
Language
Keywords
Alternative Title
Abstract
BACKGROUND: Medication nonadherence can result in poor clinical outcomes and significant costs to health care providers. When treating venous thromboembolism (VTE), subtherapeutic anticoagulation may contribute to complications such as recurrent VTE or postthrombotic syndrome. OBJECTIVES: To describe the extent, reasons for, and predictors of nonadherence to rivaroxaban for the treatment of VTE in clinical practice in the United Kingdom reported by participants of the FIRST registry. PATIENTS/METHODS: The FIRST registry was an observational, multicenter registry reporting on the use of rivaroxaban in routine clinical practice. FIRST registry participants completed an adherence screening questionnaire during their treatment and follow-up. RESULTS: In total, 1028 participants completed 1660 questionnaires over 2 years. One hundred thirteen of 1028 (11%) reported nonadherence at 28 days (interquartile range, 21-45). Reasons given for nonadherence at 1 month were forgetfulness (8.6% vs 74.7%; CONCLUSIONS: Overall adherence to rivaroxaban was high, and most nonadherence was unintentional. Identification of those at risk of nonadherence may reduce the risk of VTE recurrence and long-term complications.
Description
Citation
Publisher
License
Journal
Research and Practice in Thrombosis and Haemostasis
Volume
5
Issue
8